Prognostic Impact of MGMT Promoter Methylation in Glioblastoma - A Systematic Review
Luigi Maria Larocca
Journal of Cancer Science & Therapy, 2014
View PDFchevron_right
Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital
Larraitz Egaña
Scientific Reports, 2020
View PDFchevron_right
MGMT promoter methylation in plasma of glioma patients receiving temozolomide
Chiara Grasso
Journal of Neuro-Oncology, 2014
View PDFchevron_right
The Response to Chemo Radiation Therapy in Unresectable Glioblastoma Multiforme Patients in Relation to MGMT Promoter Methylation Status: A Study from a Single Saudi Center
Ehab Khalil
Journal of Clinical Epigenetics, 2017
View PDFchevron_right
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Guido Nikkhah, Joachim Steinbach
Clinical cancer research : an official journal of the American Association for Cancer Research, 2015
View PDFchevron_right
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial
Aline Becker
JAMA oncology, 2018
View PDFchevron_right
MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study
Paulina Śledzińska
Biomedicines
View PDFchevron_right
Influence of Intratumor Heterogeneity on the Predictivity of MGMT Gene Promoter Methylation Status in Glioblastoma
Lorena Gurrieri
Frontiers in Oncology, 2020
View PDFchevron_right
Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)
Parveen Shah
Scientific reports, 2018
View PDFchevron_right
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma
Johan Menten
European Journal of Cancer, 2009
View PDFchevron_right
MGMT Promoter Methylation and Glioblastoma: A Comparison of Analytical Methods and of Tumor Specimens
Marco Merlano
The International Journal of Biological Markers, 2015
View PDFchevron_right
Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: A Portuguese multicentre study
C. Alegria
Oncology Reports, 2010
View PDFchevron_right
The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma
svetlana tosic
Medicina, 2019
View PDFchevron_right
Prognostic significance of MGMT promoter methylation in diffuse glioma patients
svetlana tosic
Biotechnology & Biotechnological Equipment, 2019
View PDFchevron_right
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Martin Van Den Bent
Nature Reviews Neurology, 2009
View PDFchevron_right
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model
Gaspar Kitange
Journal of Neuro-Oncology, 2009
View PDFchevron_right
Correlation of Clinical Features and Methylation Status of MGMT Gene Promoter in Glioblastomas
L. Karayan-Tapon
Journal of Neuro-Oncology, 2000
View PDFchevron_right
Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study
Kalala Okito Jean-Pierre
Journal of Neuro-Oncology, 2019
View PDFchevron_right
Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma
Suely Marie
Clinics, 2011
View PDFchevron_right
Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications
Giovanni Lanza
Oncologist, 2017
View PDFchevron_right
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Raul Miguel Ortiz
Journal of Translational Medicine, 2012
View PDFchevron_right
Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With MGMT Promoter Methylation Status
G. Frezza
Journal of Clinical Oncology, 2009
View PDFchevron_right
MGMT promoter methylation in malignant gliomas
Martin Van Den Bent
Targeted Oncology, 2010
View PDFchevron_right
MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials
greg jones
Clinical Cancer Research, 2018
View PDFchevron_right
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme
Lorena Gurrieri
Future oncology (London, England), 2018
View PDFchevron_right
MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?
Domenico D'avella
Journal of Neuro-Oncology, 2012
View PDFchevron_right